In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Pharmacological stress echocardiography as a predictor of cardiovascular events in diabetic patients

Session Poster session 1

Speaker Filipa Andreia Castro

Congress : EuroEcho 2017

  • Topic : imaging
  • Sub-topic : Stress Echocardiography
  • Session type : Poster Session
  • FP Number : P298

Authors : F A Castro (Guimaraes,PT), T Lopes (Braga,PT), O Azevedo (Guimaraes,PT), M Lourenco (Guimaraes,PT), B Faria (Guimaraes,PT), I Oliveira (Guimaraes,PT), A Lourenco (Guimaraes,PT)

F A Castro1 , T Lopes2 , O Azevedo1 , M Lourenco1 , B Faria1 , I Oliveira1 , A Lourenco1 , 1Hospital Senhora da Oliveira, Serviço de Cardiologia - Guimarães - Portugal , 2University of Minho - Life and Health Sciences Research Institute (ICVS) - Braga - Portugal ,

European Heart Journal Supplements ( 2017 ) 18 ( Supplement 3 ), iii64

Introduction: Patients with diabetes mellitus (DM) have a high risk of cardiovascular (CV) events, such as myocardial infarction, revascularization or cardiac mortality. Coronary artery disease installs silently in this subgroup of patients, so pharmacological stress echocardiography (PSE) stands out as the method of choice in the diagnosis of coronary artery disease and prediction of CV events in diabetic population.

Aim: Evaluate the value of PSE in the stratification of prognosis in diabetic patients with suspected or diagnosed coronary heart disease.

Methods: Retrospective study including 297 patients with DM, who performed PES (dipyridamole or dobutamine) between 2010 and 2015. Demographic data, clinical, electrocardiographic, baseline and stress echocardiographic findings were collected to identify predictors of prognosis. We defined a combined endpoint of CV events, composed by cardiac death non-fatal, myocardial infarction non fatal and percutaneous or surgical revascularization.

Results: 194 patients (65.3%) were male and the mean age was 66±9 years. Cardiovascular risk factors were identified such as dyslipidemia (85.2%), arterial hypertension (89.9%), obesity (36.7%) and smoking (7.7%). We found history of myocardial infarction in 42.8%, angioplasty in 22.5% and bypass surgery in 12.8%. Left ventricular systolic dysfunction was detected on basal echocardiogram in 27.3% of cases. PES was performed in 55.9% of patients due to suspected coronary artery disease and in 44.1% due to diagnosed coronary heart disease. PES was performed with dobutamine in 68% and dipyridamole in 32% of patients. PES was positive in 15.2%, negative in 74.1% and inconclusive in 10.8% of patients. Mean follow-up was 2.6 years (±1.53). CV events occurred in 15.1% of patients. Using a multivariate regression analysis we identified as independent predictors of CV events the positivity of PES (p<0.001, OR 6.9, 95% 2,4-20,1), the chronic renal failure (p=0.005, OR 4.7, 95% CI 1,61-13,73) and the occurrence chest pain after PES (p=0.007, OR 3.6, 95% 1,4-9,3).

Conclusion: In this study, PES was an important independent predictor of CV events in patients with DM.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are